Adhera Therapeutics, Inc. (ATRX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | -2.11 Million USD | 130.22% |
| 2021 | -7.78 Million USD | -40.51% |
| 2020 | -5.54 Million USD | 56.17% |
| 2019 | -12.64 Million USD | 24.56% |
| 2018 | -16.75 Million USD | -169.4% |
| 2017 | -6.21 Million USD | -642.93% |
| 2016 | -837.14 Thousand USD | -125.09% |
| 2015 | 3.33 Million USD | 151.52% |
| 2014 | -6.47 Million USD | -312.29% |
| 2013 | -1.57 Million USD | 83.54% |
| 2012 | -9.54 Million USD | 67.56% |
| 2011 | -29.42 Million USD | -6.02% |
| 2010 | -27.75 Million USD | -244.93% |
| 2009 | -8.04 Million USD | 86.41% |
| 2008 | -59.22 Million USD | -13.08% |
| 2007 | -52.37 Million USD | -94.86% |
| 2006 | -26.87 Million USD | 16.44% |
| 2005 | -32.16 Million USD | -12.42% |
| 2004 | -28.6 Million USD | -1236.24% |
| 2003 | -2.14 Million USD | 84.1% |
| 2002 | -13.46 Million USD | -45.88% |
| 2001 | -9.23 Million USD | 4.74% |
| 2000 | -9.69 Million USD | -15.37% |
| 1999 | -8.4 Million USD | -833.33% |
| 1998 | -900 Thousand USD | 80.0% |
| 1997 | -4.5 Million USD | 0.0% |
| 1996 | - USD | 100.0% |
| 1995 | -100 Thousand USD | -150.0% |
| 1994 | 200 Thousand USD | 300.0% |
| 1993 | -100 Thousand USD | 67.74% |
| 1992 | -310 Thousand USD | 31.11% |
| 1991 | -450 Thousand USD | -25.0% |
| 1990 | -360 Thousand USD | 43.75% |
| 1989 | -640 Thousand USD | 40.19% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q1 | -886 Thousand USD | -154.62% |
| 2023 Q3 | -3.53 Million USD | -1404.73% |
| 2023 Q2 | 271 Thousand USD | 130.59% |
| 2022 Q4 | 1.62 Million USD | 236.42% |
| 2022 Q1 | 598 Thousand USD | 135.83% |
| 2022 Q2 | 1.8 Million USD | 202.51% |
| 2022 Q3 | -1.18 Million USD | -165.73% |
| 2022 FY | 2.35 Million USD | 130.22% |
| 2021 Q1 | -428 Thousand USD | 11.39% |
| 2021 Q3 | -3.73 Million USD | -627.43% |
| 2021 Q2 | -514 Thousand USD | -20.09% |
| 2021 FY | -7.78 Million USD | -40.51% |
| 2021 Q4 | -1.66 Million USD | 55.36% |
| 2020 Q1 | -1.83 Million USD | 55.0% |
| 2020 FY | -5.54 Million USD | 56.17% |
| 2020 Q2 | -906 Thousand USD | 50.71% |
| 2020 Q3 | -539 Thousand USD | 40.51% |
| 2020 Q4 | -483 Thousand USD | 10.39% |
| 2019 Q1 | -2.55 Million USD | 13.76% |
| 2019 Q3 | -2.55 Million USD | 8.06% |
| 2019 FY | -12.64 Million USD | 24.56% |
| 2019 Q4 | -4.08 Million USD | -59.78% |
| 2019 Q2 | -2.78 Million USD | -8.67% |
| 2018 Q2 | -4.64 Million USD | -241.48% |
| 2018 Q4 | -2.96 Million USD | 61.87% |
| 2018 Q3 | -7.77 Million USD | -67.37% |
| 2018 Q1 | -1.36 Million USD | 54.52% |
| 2018 FY | -16.75 Million USD | -169.4% |
| 2017 Q2 | -1.17 Million USD | -8.17% |
| 2017 FY | -6.21 Million USD | -642.93% |
| 2017 Q4 | -2.99 Million USD | -207.88% |
| 2017 Q1 | -1.08 Million USD | 11.48% |
| 2017 Q3 | -972.18 Thousand USD | 16.99% |
| 2016 Q1 | 1.06 Million USD | 90.54% |
| 2016 Q4 | -1.22 Million USD | -3118.8% |
| 2016 Q3 | -38 Thousand USD | 94.09% |
| 2016 FY | -837.14 Thousand USD | -125.09% |
| 2016 Q2 | -643 Thousand USD | -160.26% |
| 2015 Q2 | 904 Thousand USD | 118.36% |
| 2015 FY | 3.33 Million USD | 151.52% |
| 2015 Q3 | 1.45 Million USD | 61.39% |
| 2015 Q1 | 414 Thousand USD | -92.87% |
| 2015 Q4 | 560 Thousand USD | -61.62% |
| 2014 FY | -6.47 Million USD | -312.29% |
| 2014 Q4 | 5.8 Million USD | 181.47% |
| 2014 Q3 | -7.12 Million USD | -281.66% |
| 2014 Q2 | 3.92 Million USD | 143.19% |
| 2014 Q1 | -9.07 Million USD | -362.22% |
| 2013 Q2 | -7000.00 USD | -100.51% |
| 2013 FY | -1.57 Million USD | 83.54% |
| 2013 Q4 | -1.96 Million USD | -101.23% |
| 2013 Q3 | -976 Thousand USD | -13842.86% |
| 2013 Q1 | 1.37 Million USD | 133.96% |
| 2012 Q1 | -4.82 Million USD | 72.88% |
| 2012 FY | -9.54 Million USD | 67.56% |
| 2012 Q4 | -4.05 Million USD | -131.54% |
| 2012 Q3 | -1.75 Million USD | -262.04% |
| 2012 Q2 | 1.08 Million USD | 122.39% |
| 2011 FY | -29.42 Million USD | -6.02% |
| 2011 Q1 | -3.66 Million USD | 37.78% |
| 2011 Q2 | -3.58 Million USD | 2.18% |
| 2011 Q3 | -4.38 Million USD | -22.37% |
| 2011 Q4 | -17.78 Million USD | -305.45% |
| 2010 Q4 | -5.89 Million USD | 28.8% |
| 2010 Q3 | -8.27 Million USD | -101.71% |
| 2010 Q2 | -4.1 Million USD | 56.79% |
| 2010 FY | -27.75 Million USD | -244.93% |
| 2010 Q1 | -9.49 Million USD | -1108.92% |
| 2009 Q4 | -785 Thousand USD | 88.8% |
| 2009 Q1 | 7.28 Million USD | 159.19% |
| 2009 Q3 | -7.01 Million USD | 6.93% |
| 2009 Q2 | -7.53 Million USD | -203.45% |
| 2009 FY | -8.04 Million USD | 86.41% |
| 2008 Q3 | -16.07 Million USD | -12.13% |
| 2008 Q1 | -16.51 Million USD | -37.48% |
| 2008 FY | -59.22 Million USD | -13.08% |
| 2008 Q2 | -14.33 Million USD | 13.24% |
| 2008 Q4 | -12.3 Million USD | 23.45% |
| 2007 Q4 | -12.01 Million USD | 26.96% |
| 2007 Q3 | -16.45 Million USD | -33.02% |
| 2007 FY | -52.37 Million USD | -94.86% |
| 2007 Q2 | -12.36 Million USD | -7.17% |
| 2007 Q1 | -11.54 Million USD | -8.23% |
| 2006 FY | -26.87 Million USD | 16.44% |
| 2006 Q4 | -10.66 Million USD | -36.55% |
| 2006 Q1 | -7.84 Million USD | 12.01% |
| 2006 Q2 | -560 Thousand USD | 92.86% |
| 2006 Q3 | -7.8 Million USD | -1294.29% |
| 2005 FY | -32.16 Million USD | -12.42% |
| 2005 Q3 | -8.81 Million USD | -5.63% |
| 2005 Q4 | -8.91 Million USD | -1.18% |
| 2005 Q2 | -8.34 Million USD | -37.08% |
| 2005 Q1 | -6.08 Million USD | -2.84% |
| 2004 FY | -28.6 Million USD | -1236.24% |
| 2004 Q4 | -5.91 Million USD | 21.65% |
| 2004 Q3 | -7.55 Million USD | -0.85% |
| 2004 Q2 | -7.49 Million USD | 2.0% |
| 2004 Q1 | -7.64 Million USD | -29.19% |
| 2003 Q4 | -5.91 Million USD | 5.34% |
| 2003 FY | -2.14 Million USD | 84.1% |
| 2003 Q1 | -2.92 Million USD | 49.53% |
| 2003 Q3 | -6.25 Million USD | -148.26% |
| 2003 Q2 | 12.95 Million USD | 542.8% |
| 2002 Q1 | -2.8 Million USD | 7.44% |
| 2002 Q2 | -1.46 Million USD | 47.66% |
| 2002 Q3 | -3.4 Million USD | -132.4% |
| 2002 Q4 | -5.79 Million USD | -70.09% |
| 2002 FY | -13.46 Million USD | -45.88% |
| 2001 FY | -9.23 Million USD | 4.74% |
| 2001 Q2 | -2.06 Million USD | 10.89% |
| 2001 Q4 | -3.02 Million USD | -65.81% |
| 2001 Q3 | -1.82 Million USD | 11.54% |
| 2001 Q1 | -2.31 Million USD | -82.43% |
| 2000 FY | -9.69 Million USD | -15.37% |
| 2000 Q2 | -2.25 Million USD | -3.59% |
| 2000 Q1 | -2.17 Million USD | 22.36% |
| 2000 Q3 | -3.99 Million USD | -77.44% |
| 2000 Q4 | -1.26 Million USD | 68.24% |
| 1999 Q4 | -2.8 Million USD | -47.37% |
| 1999 Q1 | -2.2 Million USD | -83.33% |
| 1999 Q2 | -1.4 Million USD | 36.36% |
| 1999 Q3 | -1.9 Million USD | -35.71% |
| 1999 FY | -8.4 Million USD | -833.33% |
| 1998 Q3 | -200 Thousand USD | -200.0% |
| 1998 Q2 | 200 Thousand USD | 0.0% |
| 1998 Q1 | 200 Thousand USD | 110.53% |
| 1998 Q4 | -1.2 Million USD | -500.0% |
| 1998 FY | -900 Thousand USD | 80.0% |
| 1997 Q3 | -1.3 Million USD | -44.44% |
| 1997 FY | -4.5 Million USD | 0.0% |
| 1997 Q4 | -1.9 Million USD | -46.15% |
| 1997 Q2 | -900 Thousand USD | -125.0% |
| 1997 Q1 | -400 Thousand USD | 0.0% |
| 1996 Q2 | - USD | -100.0% |
| 1996 Q1 | 200 Thousand USD | 200.0% |
| 1996 Q3 | 100 Thousand USD | 0.0% |
| 1996 FY | - USD | 100.0% |
| 1995 Q2 | -200 Thousand USD | 0.0% |
| 1995 Q1 | - USD | 0.0% |
| 1995 Q3 | - USD | 100.0% |
| 1995 Q4 | -200 Thousand USD | 0.0% |
| 1995 FY | -100 Thousand USD | -150.0% |
| 1994 Q2 | 100 Thousand USD | 200.0% |
| 1994 Q3 | 100 Thousand USD | 0.0% |
| 1994 FY | 200 Thousand USD | 300.0% |
| 1994 Q4 | - USD | -100.0% |
| 1994 Q1 | -100 Thousand USD | 0.0% |
| 1993 Q3 | 200 Thousand USD | 500.0% |
| 1993 FY | -100 Thousand USD | 67.74% |
| 1993 Q4 | - USD | -100.0% |
| 1993 Q2 | -50 Thousand USD | 0.0% |
| 1992 FY | -310 Thousand USD | 31.11% |
| 1991 FY | -450 Thousand USD | -25.0% |
| 1990 FY | -360 Thousand USD | 43.75% |
| 1989 FY | -640 Thousand USD | 40.19% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -58.301% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 69.726% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 103.99% |
| Nascent Biotech, Inc. | -2.08 Million USD | -1.261% |
| Rebus Holdings, Inc. | -1.02 Million USD | -107.255% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 103.246% |
| Qrons Inc. | -789.34 Thousand USD | -167.816% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -234.278% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 96.623% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -408.81% |
| Skye Bioscience, Inc. | -37.64 Million USD | 94.384% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 97.18% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 67.853% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -673.22% |
| SQZ Biotechnologies Company | -79.46 Million USD | 97.34% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 26.912% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -16.12% |
| Mesoblast Limited | -87.95 Million USD | 97.597% |
| Marizyme, Inc. | -65.34 Million USD | 96.765% |
| Genus plc | 7.9 Million USD | 126.759% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 80.591% |
| Pharming Group N.V. | -10.54 Million USD | 79.958% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 2.572% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 43.022% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 76.097% |
| ContraFect Corporation | -65.15 Million USD | 96.755% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 56.734% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -22.377% |
| IMV Inc. | -36.48 Million USD | 94.206% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 73.771% |
| MultiCell Technologies, Inc. | -380.07 USD | -556113.329% |
| ONE Bio Corp. | 8.67 Million USD | 124.364% |
| Accustem Sciences Inc. | -3.74 Million USD | 43.573% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 95.91% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -66.833% |
| Q BioMed Inc. | -2.05 Million USD | -3.017% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 43.37% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 11.209% |
| Biomind Labs Inc. | -1.21 Million USD | -74.089% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 96.46% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 31.845% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 73.251% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -8.452% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -14015.919% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 86.68% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 63.66% |
| GB Sciences, Inc. | -1.36 Million USD | -55.25% |
| Alpha Cognition Inc. | -13.77 Million USD | 84.651% |
| HST Global, Inc. | -146.21 Thousand USD | -1345.866% |
| CSL Limited | 2.64 Billion USD | 100.08% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -20.472% |
| Halberd Corporation | -79.67 Thousand USD | -2553.246% |
| Enzolytics Inc. | -2.17 Million USD | 2.886% |
| Agentix Corp. | -1.37 Million USD | -53.834% |
| Resverlogix Corp. | -3.61 Million USD | 41.44% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 33.342% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.284% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 2257.143% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 130.529% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 46.791% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 30.142% |
| AVAX Technologies, Inc. | -6.41 Million USD | 67.039% |
| Zenith Capital Corp. | -10.59 Million USD | 80.049% |
| Genscript Biotech Corporation | -95.47 Million USD | 97.786% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -8995.603% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 49.01% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -3397.648% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -5.43% |
| Kadimastem Ltd | -3.3 Million USD | 36.083% |
| Helix BioMedix, Inc. | -1.05 Million USD | -100.179% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 44.645% |
| BioStem Technologies, Inc. | -8.48 Million USD | 75.08% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -378.964% |
| LadRx Corporation | 400.44 Thousand USD | 627.915% |
| Cell Source, Inc. | -5.32 Million USD | 60.272% |
| Regen BioPharma, Inc. | 1.02 Million USD | 306.545% |
| Regen BioPharma, Inc. | 1.02 Million USD | 306.545% |
| NovAccess Global Inc. | -4.76 Million USD | 55.674% |
| Affymax, Inc. | -14.42 Million USD | 85.344% |
| Itoco Inc. | -1.86 Million USD | -13.109% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 52.415% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -26.663% |
| Mobile Lads Corp. | -2.26 Million USD | 6.596% |
| CytoDyn Inc. | -49.84 Million USD | 95.759% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -2574.832% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -826.677% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -124.528% |
| SYBLEU INC | -180.3 Thousand USD | -1072.464% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -31.082% |
| International Stem Cell Corporation | -131 Thousand USD | -1513.74% |
| Bioxytran, Inc. | -4.28 Million USD | 50.607% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -3795.195% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 16.451% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 95.602% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -170.718% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 33.27% |
| Neutra Corp. | -233.46 Thousand USD | -805.489% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 89.582% |
| PureTech Health plc | -65.69 Million USD | 96.782% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 90.06% |
| IXICO plc | -1.17 Million USD | -79.457% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 78.705% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 96.3% |
| CSL Limited | 2.64 Billion USD | 100.08% |
| Cellectis S.A. | -103.17 Million USD | 97.951% |